Performance of a new HPV and biomarker assay in the management of hrHPV positive women: Subanalysis of the ongoing multicenter TRACE clinical trial (n > 6,000) to evaluate POU4F3 methylation as a potential biomarker of cervical precancer and cancer

Adrienn Kocsis, Tibor Takács, Csaba Jeney, Zsuzsa Schaff, Róbert Koiss, Balázs Járay, Gábor Sobel, Károly Pap, István Székely, Tamás Ferenci, Hung Cheng Lai, Miklós Nyíri, Márta Benczik

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The ongoing Triage and Risk Assessment of Cervical Precancer by Epigenetic Biomarker (TRACE) prospective, multicenter study aimed to provide a clinical evaluation of the CONFIDENCE™ assay, which comprises a human papillomavirus (HPV) DNA and a human epigenetic biomarker test. Between 2013 and 2015 over 6,000 women aged 18 or older were recruited in Hungary. Liquid-based cytology (LBC), high-risk HPV (hrHPV) DNA detection and single target host gene methylation test of the promoter sequence of the POU4F3 gene by quantitative methylation-specific polymerase chain reaction (PCR) were performed from the same liquid-based cytology sample. The current analysis is focused on the baseline cross-sectional clinical results of 5,384 LBC samples collected from subjects aged 25 years or older. The performance of the CONFIDENCE HPV™ test was found to be comparable to the cobas® HPV test with good agreement. When applying the CONFIDENCE Marker™ test alone in hrHPV positives, it showed significantly higher sensitivity with matching specificity compared to LBC-based triage. For CIN3+ histological endpoint in the age group of 25–65 and 30–65, the methylation test of POU4F3 achieved relative sensitivities of 1.74 (95% CI: 1.25–2.33) and 1.64 (95% CI: 1.08–2.27), respectively, after verification bias adjustment. On the basis of our findings, POU4F3 methylation as a triage test of hrHPV positives appears to be a noteworthy method. We can reasonably assume that its quantitative nature offers the potential for a more objective and discriminative risk assessment tool in the prevention and diagnostics of high-grade cervical intraepithelial neoplasia (CIN) lesions and cervical cancer.

Original languageEnglish
Pages (from-to)1119-1133
Number of pages15
JournalInternational Journal of Cancer
Volume140
Issue number5
DOIs
Publication statusPublished - Mar 1 2017

Fingerprint

Risk Management
Uterine Cervical Neoplasms
Methylation
Cell Biology
Triage
Biomarkers
Clinical Trials
Epigenomics
Cervical Intraepithelial Neoplasia
Hungary
DNA
Genes
Multicenter Studies
Age Groups
Prospective Studies
Polymerase Chain Reaction

Keywords

  • cervical cancer
  • epigenetics
  • high-risk HPV
  • host gene methylation
  • POU4F3 biomarker

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

Performance of a new HPV and biomarker assay in the management of hrHPV positive women : Subanalysis of the ongoing multicenter TRACE clinical trial (n > 6,000) to evaluate POU4F3 methylation as a potential biomarker of cervical precancer and cancer. / Kocsis, Adrienn; Takács, Tibor; Jeney, Csaba; Schaff, Zsuzsa; Koiss, Róbert; Járay, Balázs; Sobel, Gábor; Pap, Károly; Székely, István; Ferenci, Tamás; Lai, Hung Cheng; Nyíri, Miklós; Benczik, Márta.

In: International Journal of Cancer, Vol. 140, No. 5, 01.03.2017, p. 1119-1133.

Research output: Contribution to journalArticle

Kocsis, Adrienn ; Takács, Tibor ; Jeney, Csaba ; Schaff, Zsuzsa ; Koiss, Róbert ; Járay, Balázs ; Sobel, Gábor ; Pap, Károly ; Székely, István ; Ferenci, Tamás ; Lai, Hung Cheng ; Nyíri, Miklós ; Benczik, Márta. / Performance of a new HPV and biomarker assay in the management of hrHPV positive women : Subanalysis of the ongoing multicenter TRACE clinical trial (n > 6,000) to evaluate POU4F3 methylation as a potential biomarker of cervical precancer and cancer. In: International Journal of Cancer. 2017 ; Vol. 140, No. 5. pp. 1119-1133.
@article{9c5280e19cdc48a8b7ec8130701477ec,
title = "Performance of a new HPV and biomarker assay in the management of hrHPV positive women: Subanalysis of the ongoing multicenter TRACE clinical trial (n > 6,000) to evaluate POU4F3 methylation as a potential biomarker of cervical precancer and cancer",
abstract = "The ongoing Triage and Risk Assessment of Cervical Precancer by Epigenetic Biomarker (TRACE) prospective, multicenter study aimed to provide a clinical evaluation of the CONFIDENCE™ assay, which comprises a human papillomavirus (HPV) DNA and a human epigenetic biomarker test. Between 2013 and 2015 over 6,000 women aged 18 or older were recruited in Hungary. Liquid-based cytology (LBC), high-risk HPV (hrHPV) DNA detection and single target host gene methylation test of the promoter sequence of the POU4F3 gene by quantitative methylation-specific polymerase chain reaction (PCR) were performed from the same liquid-based cytology sample. The current analysis is focused on the baseline cross-sectional clinical results of 5,384 LBC samples collected from subjects aged 25 years or older. The performance of the CONFIDENCE HPV™ test was found to be comparable to the cobas{\circledR} HPV test with good agreement. When applying the CONFIDENCE Marker™ test alone in hrHPV positives, it showed significantly higher sensitivity with matching specificity compared to LBC-based triage. For CIN3+ histological endpoint in the age group of 25–65 and 30–65, the methylation test of POU4F3 achieved relative sensitivities of 1.74 (95{\%} CI: 1.25–2.33) and 1.64 (95{\%} CI: 1.08–2.27), respectively, after verification bias adjustment. On the basis of our findings, POU4F3 methylation as a triage test of hrHPV positives appears to be a noteworthy method. We can reasonably assume that its quantitative nature offers the potential for a more objective and discriminative risk assessment tool in the prevention and diagnostics of high-grade cervical intraepithelial neoplasia (CIN) lesions and cervical cancer.",
keywords = "cervical cancer, epigenetics, high-risk HPV, host gene methylation, POU4F3 biomarker",
author = "Adrienn Kocsis and Tibor Tak{\'a}cs and Csaba Jeney and Zsuzsa Schaff and R{\'o}bert Koiss and Bal{\'a}zs J{\'a}ray and G{\'a}bor Sobel and K{\'a}roly Pap and Istv{\'a}n Sz{\'e}kely and Tam{\'a}s Ferenci and Lai, {Hung Cheng} and Mikl{\'o}s Ny{\'i}ri and M{\'a}rta Benczik",
year = "2017",
month = "3",
day = "1",
doi = "10.1002/ijc.30534",
language = "English",
volume = "140",
pages = "1119--1133",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Performance of a new HPV and biomarker assay in the management of hrHPV positive women

T2 - Subanalysis of the ongoing multicenter TRACE clinical trial (n > 6,000) to evaluate POU4F3 methylation as a potential biomarker of cervical precancer and cancer

AU - Kocsis, Adrienn

AU - Takács, Tibor

AU - Jeney, Csaba

AU - Schaff, Zsuzsa

AU - Koiss, Róbert

AU - Járay, Balázs

AU - Sobel, Gábor

AU - Pap, Károly

AU - Székely, István

AU - Ferenci, Tamás

AU - Lai, Hung Cheng

AU - Nyíri, Miklós

AU - Benczik, Márta

PY - 2017/3/1

Y1 - 2017/3/1

N2 - The ongoing Triage and Risk Assessment of Cervical Precancer by Epigenetic Biomarker (TRACE) prospective, multicenter study aimed to provide a clinical evaluation of the CONFIDENCE™ assay, which comprises a human papillomavirus (HPV) DNA and a human epigenetic biomarker test. Between 2013 and 2015 over 6,000 women aged 18 or older were recruited in Hungary. Liquid-based cytology (LBC), high-risk HPV (hrHPV) DNA detection and single target host gene methylation test of the promoter sequence of the POU4F3 gene by quantitative methylation-specific polymerase chain reaction (PCR) were performed from the same liquid-based cytology sample. The current analysis is focused on the baseline cross-sectional clinical results of 5,384 LBC samples collected from subjects aged 25 years or older. The performance of the CONFIDENCE HPV™ test was found to be comparable to the cobas® HPV test with good agreement. When applying the CONFIDENCE Marker™ test alone in hrHPV positives, it showed significantly higher sensitivity with matching specificity compared to LBC-based triage. For CIN3+ histological endpoint in the age group of 25–65 and 30–65, the methylation test of POU4F3 achieved relative sensitivities of 1.74 (95% CI: 1.25–2.33) and 1.64 (95% CI: 1.08–2.27), respectively, after verification bias adjustment. On the basis of our findings, POU4F3 methylation as a triage test of hrHPV positives appears to be a noteworthy method. We can reasonably assume that its quantitative nature offers the potential for a more objective and discriminative risk assessment tool in the prevention and diagnostics of high-grade cervical intraepithelial neoplasia (CIN) lesions and cervical cancer.

AB - The ongoing Triage and Risk Assessment of Cervical Precancer by Epigenetic Biomarker (TRACE) prospective, multicenter study aimed to provide a clinical evaluation of the CONFIDENCE™ assay, which comprises a human papillomavirus (HPV) DNA and a human epigenetic biomarker test. Between 2013 and 2015 over 6,000 women aged 18 or older were recruited in Hungary. Liquid-based cytology (LBC), high-risk HPV (hrHPV) DNA detection and single target host gene methylation test of the promoter sequence of the POU4F3 gene by quantitative methylation-specific polymerase chain reaction (PCR) were performed from the same liquid-based cytology sample. The current analysis is focused on the baseline cross-sectional clinical results of 5,384 LBC samples collected from subjects aged 25 years or older. The performance of the CONFIDENCE HPV™ test was found to be comparable to the cobas® HPV test with good agreement. When applying the CONFIDENCE Marker™ test alone in hrHPV positives, it showed significantly higher sensitivity with matching specificity compared to LBC-based triage. For CIN3+ histological endpoint in the age group of 25–65 and 30–65, the methylation test of POU4F3 achieved relative sensitivities of 1.74 (95% CI: 1.25–2.33) and 1.64 (95% CI: 1.08–2.27), respectively, after verification bias adjustment. On the basis of our findings, POU4F3 methylation as a triage test of hrHPV positives appears to be a noteworthy method. We can reasonably assume that its quantitative nature offers the potential for a more objective and discriminative risk assessment tool in the prevention and diagnostics of high-grade cervical intraepithelial neoplasia (CIN) lesions and cervical cancer.

KW - cervical cancer

KW - epigenetics

KW - high-risk HPV

KW - host gene methylation

KW - POU4F3 biomarker

UR - http://www.scopus.com/inward/record.url?scp=85010383572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010383572&partnerID=8YFLogxK

U2 - 10.1002/ijc.30534

DO - 10.1002/ijc.30534

M3 - Article

C2 - 27874187

AN - SCOPUS:85010383572

VL - 140

SP - 1119

EP - 1133

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 5

ER -